| Literature DB >> 4956 |
L Hansson, B E Karlberg, H Aberg, A Westerlund, S Jameson, N C Henningsen.
Abstract
A report is given from an on-going multicenter trial in Sweden, in which 117 hypertensive patients have been treated with a new cardioselective beta-adrenergic blocking agent, atenolol (ICI 66.082, Tenormin) for an average of six months (range 2-21). Statistically significant reductions of BP were observed, recumbent by 29/19 mmHg (p less than 0.0001) and standing by 28/18 mmHg (p less than 0.0001). Few and comparatively mild side-effects were seen.Entities:
Mesh：
Substances：
Year: 1976 PMID： 4956 DOI： 10.1111/j.0954-6820.1976.tb06729.x
Source DB: PubMed Journal: Acta Med Scand ISSN： 0001-6101